Comparison of Efficacy and Safety between Warfarin, Rivaroxaban and Edoxaban in patients with acute pulmonary embolism in showa university

Comparison of Efficacy and Safety between Warfarin, Rivaroxaban and Edoxaban in patients with acute pulmonary embolism in showa university - Edo-warivashi study in showa university

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020069

Enrollment

100

Registered

2015-12-10

Start date

2015-12-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pulmonary embolism

Interventions

Warfarin administration for 6 months with PTINR betweeen 2.00 and 3.00 Rivaroxaban administration at the dose of 15mg twice a day in the first 3 weeks. Subsequently,Rivaroxaban administration at th

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with acute pulmonary embolism who are and hospitalized in Showa University Hospital, Showa University Fujigaoka Hospital and Showa University Koto Toyosu Hospital and needed intensive care

Exclusion criteria

Exclusion criteria: CrCL less than 30ml/min Patients with acute bleeding Patients with active malignancy Patients needed PCPS,IABP and aortic sheathes Contraindication of each drug

Design outcomes

Primary

Measure	Time frame
Score of Central Disease Score and Thrombus volume in pulmonary vein measured by CT (if possible)	—

Secondary

Measure	Time frame
1)CT index score 2)Coagulation test 3)Change in UCG 4)Length of hospital stay and CCU 5)Length of disappearance of pulmonary embolism from an initial day	—

Countries

Japan

Contacts

Public ContactNorikazu Watanabe Toigyu Matsui

Department of Medicine Showa university Division of Cardiology

n-watanabe@med.showa-u.ac.jp0337848000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026